Literature DB >> 23241141

Anti-Ge3 causes late-onset hemolytic disease of the newborn: the fourth case in three Hispanic families.

Lisa Lee Pate1, Jessica C Myers, Jonathan P Palma, Maurene Viele, Susan A Galel, Zenaida Ferrer, Christopher L Gonzalez, William E Benitz, George Garratty, Magali J Fontaine.   

Abstract

BACKGROUND: The Gerbich (Ge) blood group system consists of 11 antigens carried on red blood cell (RBC) membrane glycophorins C and D; of these, Ge:3 antigen is of high prevalence, and the anti-Ge3 is found to be clinically significant. CASE REPORT: A 34-week neonate born to a Hispanic mother with anti-Ge3 developed late-onset hemolysis with hyperbilirubinemia and was successfully treated with transfusions from her mother. Relevant clinical findings and laboratory results for this case are summarized and compared to three other previously reported cases; all babies were born from a mother of Hispanic ethnicity.
CONCLUSION: Hemolytic disease of the fetus and new born associated with anti-Ge3 is rare but should be considered when working up a broadly reactive RBC antibody screen in women of Hispanic ethnicity. Early identification of pregnant women with anti-Ge3 is recommended for prenatal transfusion planning and close monitoring of the newborn infant for evidence of late-onset anemia.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241141      PMCID: PMC4826565          DOI: 10.1111/trf.12027

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  24 in total

1.  The expression of human blood group antigens during erythropoiesis in a cell culture system.

Authors:  M J Southcott; M J Tanner; D J Anstee
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

2.  Time-course expression of polypeptides carrying blood group antigens during human erythroid differentiation.

Authors:  V Bony; P Gane; P Bailly; J P Cartron
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

3.  Anti-glycophorin C induces mitochondrial membrane depolarization and a loss of extracellular regulated kinase 1/2 protein kinase activity that is prevented by pretreatment with cytochalasin D: implications for hemolytic disease of the fetus and newborn caused by anti-Ge3.

Authors:  Jonathan A Micieli; Duncheng Wang; Gregory A Denomme
Journal:  Transfusion       Date:  2010-08       Impact factor: 3.157

4.  Pure red cell anemia due to auto antibodies; immune-type of aplastic anemia, erythroblastopenia.

Authors:  C GASSER
Journal:  Sang       Date:  1955

5.  Decreased bone marrow function in hemolytic disease of newborn: report of a case with severe anemia and prolonged persistance of antibodies.

Authors:  B LINDQUIST; L RYTTINGER
Journal:  Acta Paediatr       Date:  1959-09       Impact factor: 2.299

6.  Damage of the bone marrow due to Rh antibody.

Authors:  E R GIBLETT; J E VARELA; C A FINCH
Journal:  Pediatrics       Date:  1956-01       Impact factor: 7.124

7.  Late onset neonatal anaemia due to maternal anti-Ge: possible association with destruction of eythroid progenitors.

Authors:  P A Arndt; G Garratty; G Daniels; C A Green; A M Wilkes; P Hunt; J Do; S Glenn; D Peterson
Journal:  Transfus Med       Date:  2005-04       Impact factor: 2.019

8.  Hemolytic disease of the newborn: progenitor cells and late effects.

Authors:  N L Luban
Journal:  N Engl J Med       Date:  1998-03-19       Impact factor: 91.245

Review 9.  A mild acute hemolytic transfusion reaction in a patient with alloanti-Ge3: a case report and review of the literature.

Authors:  Mariah R Baughn; Patricia Whitacre; Grace S Lo; Suchitra Pandey; Thomas A Lane
Journal:  Transfusion       Date:  2011-03-10       Impact factor: 3.157

10.  Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancy.

Authors:  D J van Wamelen; F J Klumper; M de Haas; R H Meerman; I L van Kamp; D Oepkes
Journal:  Obstet Gynecol       Date:  2007-05       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.